TrialAdvances in therapy2023

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.

Marla Dubinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.